Ahmad Mokatrin

6.4k total citations
19 papers, 887 citations indexed

About

Ahmad Mokatrin is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Ahmad Mokatrin has authored 19 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Immunology. Recurrent topics in Ahmad Mokatrin's work include Cancer Immunotherapy and Biomarkers (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Ahmad Mokatrin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Ahmad Mokatrin collaborates with scholars based in United States, France and Spain. Ahmad Mokatrin's co-authors include Marcin Kowanetz, Jeffrey A. Sosman, Omid Hamid, Daniel S. Chen, Gregg Fine, F. Stephen Hodi, Michael S. Gordon, Dan M. Granoff, Howard V. Raff and Jean‐Charles Soria and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Cancer Research.

In The Last Decade

Ahmad Mokatrin

19 papers receiving 847 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ahmad Mokatrin United States	12	620	385	194	135	117	19	887
Beata Kotowicz Poland	14	232 0.4×	139 0.4×	63 0.3×	112 0.8×	142 1.2×	48	562
K Rygaard Denmark	11	248 0.4×	161 0.4×	51 0.3×	135 1.0×	307 2.6×	14	735
Carine El Sissy France	11	202 0.3×	204 0.5×	39 0.2×	59 0.4×	56 0.5×	25	451
Yeh Chen Lee Australia	13	318 0.5×	70 0.2×	88 0.5×	137 1.0×	253 2.2×	51	791
Nobuhiro Ikuno Japan	11	298 0.5×	116 0.3×	147 0.8×	152 1.1×	166 1.4×	19	656
Lyndal Anderson Australia	14	170 0.3×	140 0.4×	72 0.4×	144 1.1×	217 1.9×	51	768
Barbara Olszewska-Pazdrak United States	11	85 0.1×	229 0.6×	197 1.0×	258 1.9×	150 1.3×	14	684
Yi Cheng China	12	400 0.6×	125 0.3×	318 1.6×	74 0.5×	165 1.4×	27	719
Vincent Vanheule Belgium	11	253 0.4×	270 0.7×	36 0.2×	60 0.4×	191 1.6×	16	579
Sigrun Hess Germany	13	173 0.3×	515 1.3×	29 0.1×	81 0.6×	172 1.5×	14	714

Countries citing papers authored by Ahmad Mokatrin

Since Specialization

Citations

This map shows the geographic impact of Ahmad Mokatrin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmad Mokatrin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmad Mokatrin more than expected).

Fields of papers citing papers by Ahmad Mokatrin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmad Mokatrin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmad Mokatrin. The network helps show where Ahmad Mokatrin may publish in the future.

Co-authorship network of co-authors of Ahmad Mokatrin

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmad Mokatrin. A scholar is included among the top collaborators of Ahmad Mokatrin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmad Mokatrin. Ahmad Mokatrin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Siddiqi, Tanya, Steven Coutré, Matthew McKinney, et al.. (2022). Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia & lymphoma. 63(7). 1580–1588. 2 indexed citations

Ninomoto, Joi, Ahmad Mokatrin, Taisei Kinoshita, et al.. (2020). Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. Hematology. 25(1). 112–117. 12 indexed citations

Miklos, David B., Madan Jagasia, Hildegard Greinix, et al.. (2017). A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease.. Journal of Clinical Oncology. 35(15_suppl). TPS7072–TPS7072. 4 indexed citations

Spira, Alexander I., Keunchil Park, Julien Mazières, et al.. (2015). Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).. Journal of Clinical Oncology. 33(15_suppl). 8010–8010. 103 indexed citations

Rizvi, Naiyer A., Laura Q.M. Chow, Luc Dirix, et al.. (2014). Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 32(15_suppl). TPS8123–TPS8123. 20 indexed citations

Soria, J.C., Scott Gettinger, Michael S. Gordon, et al.. (2014). Biomarkers Associated with Clinical Activity of Pd-L1 Blockade in Non-Small Cell Lung Cancer (Nsclc) Patients (Pts) in a Phase I Study of Mpdl3280A. Annals of Oncology. 25. iv465–iv465. 3 indexed citations

Gordon, Michael S., Omid Hamid, John D. Powderly, et al.. (2013). Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. Cancer Research. 73(8_Supplement). LB–288. 11 indexed citations

Kohrt, Holbrook E., Marcin Kowanetz, Scott Gettinger, et al.. (2013). Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1. Journal for ImmunoTherapy of Cancer. 1(S1). 7 indexed citations

Herbst, Roy S., Michael S. Gordon, Gregg Fine, et al.. (2013). A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. Journal of Clinical Oncology. 31(15_suppl). 3000–3000. 157 indexed citations

10.

Hamid, Omid, Jeffrey A. Sosman, Donald P. Lawrence, et al.. (2013). Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).. Journal of Clinical Oncology. 31(15_suppl). 9010–9010. 139 indexed citations

11.

Powderly, John D., Hartmut Koeppen, F. Stephen Hodi, et al.. (2013). Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.. Journal of Clinical Oncology. 31(15_suppl). 3001–3001. 51 indexed citations

12.

Cho, Daniel C., Jeffrey A. Sosman, Mario Sznol, et al.. (2013). Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 31(15_suppl). 4505–4505. 84 indexed citations

13.

Spigel, David R., Scott Gettinger, Leora Horn, et al.. (2013). Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 31(15_suppl). 8008–8008. 80 indexed citations

14.

Ford, Anthony, Daniel Gennevois, Margaret L. Harbison, et al.. (2003). A randomized crossover study to evaluate Ro 115–1240, a selective α _1A/1L ‐adrenoceptor partial agonist in women with stress urinary incontinence. British Journal of Urology. 93(1). 78–83. 35 indexed citations

15.

Choppin, Agnès, et al.. (2001). Evaluation of oral Ro70-0004/003, an α1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction. International Journal of Impotence Research. 13(3). 157–161. 19 indexed citations

16.

Granoff, Dan M., Susan E. Maslanka, George M. Carlone, et al.. (1998). A Modified Enzyme-Linked Immunosorbent Assay for Measurement of Antibody Responses to Meningococcal C Polysaccharide That Correlate with Bactericidal Responses. Clinical and Diagnostic Laboratory Immunology. 5(4). 479–485. 101 indexed citations

17.

Granoff, Dan M., et al.. (1997). MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infection and Immunity. 65(5). 1710–1715. 48 indexed citations

18.

MacDonald, Noni, Scott A. Halperin, Barbara Law, et al.. (1996). BIOCINE® MENINGOCOCCAL C (MenC) CONJUGATE VACCINE ELICITS HIGH TITERS OF SERUM BACTERICIDAL ACTIVITY IN TODDLERS. ▴ 1053. Pediatric Research. 39. 178–178. 3 indexed citations

19.

Smith, William, Steven G. Chrysant, Thomas S. Parker, et al.. (1995). 901-82 A Multicenter Controlled Trial of a Novel Metabolic Active Compound (Ranolazine) in Chronic Stable Angina Patients. Journal of the American College of Cardiology. 25(2). 24A–25A. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact